524703 — Sandu Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹583.23m
- IN₹571.78m
- IN₹672.81m
- 68
- 41
- 37
- 46
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 484 | 588 | 655 | 653 | 673 |
Cost of Revenue | |||||
Gross Profit | 233 | 243 | 298 | 342 | 347 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 475 | 572 | 632 | 634 | 656 |
Operating Profit | 9.01 | 16 | 23.4 | 19.7 | 17.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 9.19 | 16.8 | 23.2 | 22.2 | 20.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | 7.2 | 10.9 | 15.9 | 15.2 | 14.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 7.2 | 10.9 | 15.9 | 15.2 | 14.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 7.2 | 10.9 | 15.9 | 15.2 | 14.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.02 | 1.54 | 1.87 | 1.61 | 1.51 |
Dividends per Share |